This 79 yo man has a pigmented lesion that has been slowly
enlarging on his right arm for around a decade.
O/E: There is a 3 cm
pigmented patch with a subtle play of color on the dorsal surface of his right
arm. The border is slightly irregular. Dermatoscopy confirms the play of color
showing variations in brown patches containing black dots admixed with reticular
hypopigmented areas.
Pathology: A 4 mm
punch biopsy was taken. This showed
atypical melanocytic hyperplasia arranged in nests and single cells at and above
the dermal epidermal junction and extending along the adnexae. (Photomicrographs courtesy of Dr. Lynne Goldberg, Department of Dermatology, Boston University School of Medicine)
Diagnosis: consistent with melanoma in situ (MIS).
Questions:
1) Is it possible to suspect MIS on dermatoscopy over melanoma in this case?
2) Although excision is the preferable treatment, would Mohs, or even imiquimod be acceptable alternatives?
3) How likely is this lesion to become invasive? It's been present now for 10 years or greater.
4) Under what circumstances would "active surveillance" be appropriate.
4) Under what circumstances would "active surveillance" be appropriate.
References:
1. M A Pizzichetta
et.al.
Dermoscopic Criteria for Melanoma in Situ Are Similar to
Those for Early Invasive Melanoma. Cancer, 91 (5), 992-7 2001
2. Kevin Phan, Asad Loya. Mohs Micrographic Surgery Versus
Wide Local Excision for Melanoma in Situ: Analysis of a Nationwide Database.
Int. J. Dermatol 58 (6), 697-702, Jun 2019
Conclusion:
Adjusted
analyses demonstrated no differences in overall survival or cancer-specific
survival between MIS patients treated with MMS compared with WLE.
3. Long-Term
Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A
Retrospective Review
Andrew
J Park et. al. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5%
Imiquimod Cream: A Retrospective Review. Dermatol Surg: 43 (8), 1017-1022 Aug
2017
Results:
Of 12 patients with histologically confirmed MIS treated with topical 5%
imiquimod cream, there were 2 recurrences (17%) during a median follow-up time
of 5.5 years.
Conclusion:
Although surgery is still considered the gold standard for the treatment of
MIS, imiquimod may represent a potentially effective noninvasive treatment
option for patient who are not surgical candidates.
4. D Tio, et. al. Variation in the Diagnosis and Clinical
Management of Lentigo Maligna Across Europe: A Survey Study Among European
Association of Dermatologists and Venereologists Members. J Euro Acad Dermatol,
32 (9), 1476-1484 2018